2-hydroxyethyl salicylate

Structural formula
General
Surname	2-hydroxyethyl salicylate
other names	Hydroxyethyl salicylate; 2-hydroxybenzoic acid 2-hydroxyethyl ester; Salicylic acid monoethylene glycol ester; Glycol salicylate; Spirosal; GLYCOL SALICYLATE ( INCI ) ;
Molecular formula	C 9 H 10 O 4
Brief description	colorless odorless solid
External identifiers / databases
EC number	201-737-2
ECHA InfoCard	100.001.580
PubChem	6880
ChemSpider	6616
DrugBank	DB11323
Wikidata	Q117422
Drug information
ATC code	M02 AC
Drug class	analgesic
properties
Molar mass	182.18 g mol −1
Physical state	firmly
density	1.25 g cm −3
Melting point	~ 30 ° C
boiling point	150–155 ° C (5 hPa)
Vapor pressure	10 mPa (20 ° C)
solubility	poor in water (13.1 g l −1 at 20 ° C)
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances Caution
H and P phrases	H: 302
	P: 301 + 312
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Salicylic acid 2-hydroxyethyl ester is the hydroxyethyl ester of salicylic acid . It is a non-steroidal anti-inflammatory drug and analgesic that is usually administered for percutaneous absorption in the form of an ointment or gel.

effect

The compound is the esterification product of salicylic acid with ethylene glycol . The pharmacological activity can be traced back to the salicylic acid residue. The mechanism of action consists in the inhibition of cyclooxygenase , an enzyme that plays a central role in triggering inflammation. As far as is known, the ethylene glycol contributes nothing to the pharmacological activity of the 2-hydroxyethyl salicylate.

It is excreted via the kidneys with the urine .

application

It is mainly used for rheumatic complaints, closed injuries, diseases of the spine, back pain, shoulder-arm pain, muscle tension, lumbago , neuralgia of the sciatic nerve , tendonitis , periostitis or bursitis . Contraindications are glucose-6-phosphate dehydrogenase deficiency, extensive skin inflammation, eczema and psoriasis. In addition, extensive long-term treatment of pregnant women, babies, toddlers and patients with previously damaged kidneys should be avoided.

Trade names

Monopreparations

Salhumin Gel (D), Venofundin (CH), Voluven (CH), Dr. Cabana rheumatoid gel (A).

Combination preparations

Dolacut Gel (A), Etrat (A), Mobilisin (A), Moviflex (A), Rubriment (A), Sportino Akut (D), Assan (CH), Dolo Arthrosenix (CH), Histalgan (CH), Sportusal ( CH), Venugel (CH), Venucreme (CH).

Web links

EMEA: Hydroxyethyl Salicylate - Summary Report ( Memento of July 10, 2007 in the Internet Archive ) (PDF, English; 128 kB)

Individual evidence

↑ Entry on GLYCOL SALICYLATE in the CosIng database of the EU Commission, accessed on February 16, 2020.
↑ ^a ^b ^c ^d ^e ^f ^g Entry on 2-hydroxyethyl salicylate in the GESTIS substance database of the IFA , accessed on December 21, 2019(JavaScript required) .
↑ Data sheet (2-hydroxyethyl) salicylate (PDF) from Merck , accessed on September 15, 2016.
↑ AM comp. d. Switzerland, as of February 2016.
↑ AGES PharmMed, as of February 2016.

[CosIng-1] Entry on GLYCOL SALICYLATE in the CosIng database of the EU Commission, accessed on February 16, 2020.

[GESTIS-2] ↑ ^a ^b ^c ^d ^e ^f ^g Entry on 2-hydroxyethyl salicylate in the GESTIS substance database of the IFA , accessed on December 21, 2019(JavaScript required) .

[Merck-3] Data sheet (2-hydroxyethyl) salicylate (PDF) from Merck , accessed on September 15, 2016.

[4] AM comp. d. Switzerland, as of February 2016.

[5] AGES PharmMed, as of February 2016.